General Motors Stock Forecast Today12-Month Stock Price Forecast:$59.7123.40% Upside HoldBased on 20 Analyst RatingsHigh Forecast$96.00Average Forecast$59.71Low Forecast$34.00General Motors Stock Forecast DetailsU.S. auto giant General Motors NYSE: GM recently made headlines with the announcement of a new $6 billion share buyback program. This move continues the company’s aggressive efforts to reduce its outstanding share count. But what’s the reasoning behind GM’s decision to allocate such a large sum towa ...

Like many of its defense peers, General Dynamics (NYSE: GD ) has seen its stock price depreciate during the beginning of 2025. The company delivered its Q4-2024 results on the 29 th of January which came inEarly 30s 'buy and hold' investor trying to achieve financial freedom to the greatest extent possible. Main focus within dividend growth investing & value. I've been investing for 10+ years and worked across several industries including finance, logistics, oil and pharma. Holding a Graduate Diploma within ...

Shares of food and essentials companies Dollar General (DG -5.59%), PepsiCo (PEP -3.14%), and The Hershey Company (HSY -4.12%) all fell on Wednesday, down 5.4%, 2.9%, and 4%, respectively, as of 2:45 p.m. ET.The across-the-board declines in these consumer staples names can likely be attributed to the House of Representatives passing its budget reconciliation bill last night. While the bill still has to go through committee meetings and also pass the Senate, analysts believe there's a high probability of cut ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The auto industry is in the spotlight today, as several major stocks react to earnings reports, strategic moves, and executive changes. Investors are closely watching General Motors Co (NYSE:GM), Stellantis NV (NYSE:STLA), and Lucid Group Inc (NASDAQ:LCID) amid these developments.General Motors announced a 25% increase in its quarterly dividend to 15 cents per share and unveiled a $6 billion stock buyback plan, with $2 billion in repurchases set for the second quarter. In response, GM has surged 6.9% to $49 ...

DETROIT – General Motors is raising its quarterly dividend and initiating a new $6 billion share repurchase program as the company attempts to reward investors amid slowing industry sales and profits.GM announced Wednesday it is increasing its quarterly dividend by 25% to 15 cents per share — matching that of crosstown rival Ford Motor. The higher dividend is expected to take effect with the company's next planned payout, scheduled to be announced in April.Under the $6 billion repurchase plan, $2 billion in ...

As a presidential candidate, Donald Trump liked to call himself "tariff man." Now that he's back in the White House, he's living up to his self-given nickname. Trump has levied 10% tariffs on imports from China. He has announced plans to implement reciprocal tariffs on all U.S. trading partners. The president intends to impose 25% tariffs on all aluminum, steel, automobiles, pharmaceuticals, and computer chips imported to the U.S. And while a 25% tariff on all imports from Canada and Mexico was temporarily ...

Group 1 - Intellabridge Technology Corporation will hold its annual general meeting virtually on April 11, 2025, at 10:00 a.m. (EST) [1] - Shareholders are encouraged to access the meeting materials posted on the company's profile on www.sedarplus.ca [2] - Voting will not be possible during the virtual meeting, and all proxies must be submitted by April 9, 2025, at 10:00 a.m. (Toronto time) [3][4] Group 2 - Intellabridge is a fintech company focused on impact finance, aiming to make every transaction positively impact the world through its Karma cashback solutions and automated donations to charitable organizations [6]

Group 1 - The article emphasizes a dividend-focused value investment strategy that prioritizes capital preservation and steady income growth [1] - The author discusses a diversified dividend stock portfolio that includes high-quality value stocks with meaningful growth potential and long-term safety [1] Group 2 - The author has disclosed a long position in shares of several defense and aerospace companies, including LMT, LHX, NOC, RTX, and GD [2] - The article is presented as a personal opinion and does not constitute investment or tax advice, highlighting the author's status as a private investor [3]

Core Insights - Alzamend Neuro, Inc. is set to initiate the first of five phase II clinical studies for AL001, targeting conditions such as Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, with the first study expected to start in Q2 2025 [1][2] - The collaboration with Massachusetts General Hospital aims to investigate AL001's unique properties, particularly its lithium delivery in the brain, which may lead to safer and more effective treatments compared to existing lithium salts [2][3] - AL001 has the potential to eliminate the need for lithium therapeutic drug monitoring, which could significantly improve treatment outcomes for patients with bipolar disorder and other conditions [3][4] Company Overview - Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder [6] - The company's pipeline includes two main candidates: AL001, a novel lithium-delivery system, and ALZN002, a cell-based therapeutic vaccine aimed at combating Alzheimer's by removing beta-amyloid from the brain [6] Product Details - AL001 is designed to provide the benefits of marketed lithium salts while reducing associated toxicities, with a maximum tolerated dose identified in previous studies that minimizes the need for therapeutic drug monitoring [5] - The formulation of AL001 aims to enhance brain absorption of lithium while lowering systemic exposure, potentially mitigating risks linked to traditional lithium therapies [5][3]